HK Stock Market Move | XTALPI(02228) up by over 6% again, RTX-117 clinical approval, further validation of the value of XTALPIAI platform.

XTALPI (02228) has risen by more than 6%, with a cumulative increase of over 40% within the month. As of the time of release, it has risen by 6.18% to 13.75 Hong Kong dollars, with a trading volume of 8.19 billion Hong Kong dollars. On the news front, on January 7th, JingTai Technology announced that Revir, a subsidiary of the company, has received approval from the National Medical Products Administration for clinical trials for its small molecule drug RTX-117. The Phase I clinical trial is scheduled to start in the first quarter of 2026. This pipeline is the first innovative drug in China targeting Charcot-Marie-Tooth disease (CMT), and it is also the first project to enter clinical trials among a series of rare disease drug pipelines developed by Revir and JingTai Technology with the assistance of AI and Siasun Robot & Automation. Guolian Minsheng Securities released a research report stating that XTALPI has formed a moat in the field of AI pharmaceuticals with its accumulation of software and hardware technology, platform business model, and key competitive position in the sector. The firm believes that the approval of RTX-117 for clinical trials marks the period of value realization for its technology platform, and with the continuous expansion of its pipeline, there is a wide space for performance elasticity and valuation reshaping.